Amgen Inc. (LON: 0R0T)

Market Cap	119.34B
Revenue (ttm)	24.27B
Net Income (ttm)	3.16B
Shares Out	n/a
EPS (ttm)	5.84
PE Ratio	37.81
Forward PE	n/a
Dividend	7.09 (2.61%)
Ex-Dividend Date	Feb 14, 2025

Volume	6,413
Average Volume	3,127
Open	274.82
Previous Close	272.50
Day's Range	272.66 - 274.82
52-Week Range	253.20 - 330.26
Beta	n/a
RSI	55.41
Earnings Date	Feb 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 26,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.

Financial numbers in USD